{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:10:44Z","timestamp":1788948644230,"version":"build-2803163510"},"reference-count":141,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Tyrosine kinase 2 (TYK2) inhibition has recently emerged as a novel therapeutic strategy in dermatology, targeting key cytokine pathways involved in immune-mediated inflammatory diseases. Deucravacitinib, an oral, selective TYK2 inhibitor that binds the regulatory pseudokinase domain, modulates signalling mediated by IL-12, IL-23 and type I interferons whilst sparing the broader JAK family, thereby providing targeted immunomodulation with a potentially improved safety profile compared with conventional JAK inhibitors. Pivotal randomized clinical trials have demonstrated robust efficacy and sustained responses in moderate-to-severe plaque psoriasis and psoriatic arthritis, establishing deucravacitinib as an effective systemic therapeutic option. However, clinical trials only partially capture the complexity of cases encountered in routine dermatological practice. In this context, this narrative review summarizes the current clinical evidence on deucravacitinib in dermatology, with a particular focus on real-world data and emerging off-label applications. Real-world studies in psoriasis consistently confirm rapid clinical improvement, durable responses and favourable tolerability across heterogeneous patient populations, including individuals with prior biologic exposure and those with involvement of difficult-to-treat areas such as the scalp, nails, palms and soles. Beyond psoriasis, an expanding body of evidence from case series and observational reports suggests potential therapeutic benefits of TYK2 inhibition in several inflammatory and autoimmune dermatological conditions, including cutaneous lupus erythematosus, dermatomyositis, alopecia areata, lichen planus, granuloma annulare, pityriasis rubra pilaris, overlapping psoriasis\/eczema and cutaneous sarcoidosis. These observations highlight the broad immunomodulatory potential of TYK2 inhibition across diverse cytokine-driven pathways implicated in dermatological diseases. Although current evidence outside psoriasis remains limited and largely derived from small case series, the accumulating clinical experience suggests that deucravacitinib may represent a versatile therapeutic option in patients with refractory or complex disease phenotypes. Ongoing clinical trials and future realworld studies will be crucial to better define the longterm efficacy, safety and optimal therapeutic positioning of deucravacitinib across the spectrum of dermatological disorders.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-deucravacitinib-in-dermatology-current-indication-and-existing-off-label-data<\/jats:p>","DOI":"10.7573\/dic.2026-4-1","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:58:22Z","timestamp":1781272702000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Deucravacitinib in dermatology: current indication and existing off-label data"],"prefix":"10.7573","volume":"15","author":[{"given":"Michela","family":"D\u2019Agostino","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05290cv24","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Naples Federico II"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05290cv24","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Naples Federico II"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nello","family":"Tommasino","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05290cv24","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Naples Federico II"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05290cv24","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Naples Federico II"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tVu A, Maloney V, Gordon KB. Deucravacitinib in moderate-to-severe psoriasis. Immunotherapy. 2022;14(16):1279\u20131290. https:\/\/doi.org\/10.2217\/imt-2022-0109","DOI":"10.2217\/imt-2022-0109"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tBirkenmaier I, Sarikaya Solak S, Maul JT. Deucravacitinib: long-term safety and efficacy reaffirm its place in the psoriasis treatment landscape. J Eur Acad Dermatol Venereol. 2025;39(7):1220\u20131221. https:\/\/doi.org\/10.1111\/jdv.20751","DOI":"10.1111\/jdv.20751"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tPotestio L, Ruggiero A, Fabbrocini G, Martora F, Megna M. Effectiveness and safety of deucravacitinib for the management of psoriasis: a review of the current literature. Psoriasis. 2023;13:19\u201326. https:\/\/doi.org\/10.2147\/ PTT.S407647","DOI":"10.2147\/PTT.S407647"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tRusi\u00f1ol L, Puig L. Tyk2 targeting in immune-mediated inflammatory diseases. Int J Mol Sci. 2023;24(4):3391. https:\/\/ doi.org\/10.3390\/ijms24043391","DOI":"10.3390\/ijms24043391"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tMiot HA, Criado PR, de Castro CCS, Ianhez M, Talhari C, Ramos PM. JAK-STAT pathway inhibitors in dermatology. An Bras Dermatol. 2023;98(5):656\u2013677. https:\/\/doi.org\/10.1016\/j.abd.2023.03.001","DOI":"10.1016\/j.abd.2023.03.001"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tFoggi G, D\u2019Oria F, Falcidia C, et al. JAK-inhibitors beyond the label: emerging applications in dermatology. Medicina. 2026;62(1):190. https:\/\/doi.org\/10.3390\/medicina62010190","DOI":"10.3390\/medicina62010190"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tDamsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736\u2013744. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.005","DOI":"10.1016\/j.jaad.2016.12.005"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tG\u00fcnd\u00fcz \u00d6. JAK\/STAT pathway modulation: does it work in dermatology? Dermatol Ther. 2019;32(3):e12903. https:\/\/ doi.org\/10.1111\/dth.12903","DOI":"10.1111\/dth.12903"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tRamakrishna C, Mason A, Edwards CJ. Tyrosine kinase 2 inhibitors in autoimmune diseases. Autoimmun Rev. 2024;23(11):103649. https:\/\/doi.org\/10.1016\/j.autrev.2024.103649","DOI":"10.1016\/j.autrev.2024.103649"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tBiswas S, Bieber K, Manz RA. IL-10 revisited in systemic lupus erythematosus. Front Immunol. 2022;13:970906. https:\/\/ doi.org\/10.3389\/fimmu.2022.970906","DOI":"10.3389\/fimmu.2022.970906"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tDanese S, Peyrin-Biroulet L. Selective tyrosine kinase 2 inhibition for treatment of inflammatory bowel disease: new hope on the rise. Inflamm Bowel Dis. 2021;27(12):2023\u20132030. https:\/\/doi.org\/10.1093\/ibd\/izab135","DOI":"10.1093\/ibd\/izab135"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tJo CE, Gooderham M, Beecker J. TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors. Int J Dermatol. 2022;61(2):139\u2013147. https:\/\/doi.org\/10.1111\/ijd.15605","DOI":"10.1111\/ijd.15605"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tHoy SM. Deucravacitinib: first approval. Drugs. 2022;82(17):1671\u20131679. https:\/\/doi.org\/10.1007\/s40265-022-01796-y","DOI":"10.1007\/s40265-022-01796-y"},{"key":"ref13","unstructured":"14.\tEuropean Medicines Agency. Sotyktu, INN deucravacitinib European Medicines Agency Product information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sotyktu. Accessed March 1, 2026."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tZhang Y, Chen T, Pan W, Li Z. A real world study on the effectiveness and safety of deu-cravacitinib in the treatment of moderate-to-severe plaque psoriasis in China. [Chinese] Zhejiang Da Xue Xue Bao Yi Xue Ban. 2025;54(5):653\u2013660. https:\/\/doi.org\/10.3724\/zdxbyxb-2025-0432","DOI":"10.3724\/zdxbyxb-2025-0432"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tShiba M, Hagino T, Saeki H, Fujimoto E, Kanda N. The sustainability of week 16 responses to deucravacitinib treatment for patients with psoriasis. J Dermatol. 2025;52(8):e740\u2013e741. https:\/\/doi.org\/10.1111\/1346-8138.17812","DOI":"10.1111\/1346-8138.17812"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tHagino T, Onda M, Saeki H, Fujimoto E, Kanda N. Effectiveness of deucravacitinib for genital, nail and scalp lesions in patients with psoriasis: a 24-week real-world study. Clin Exp Dermatol. 2024;50(1):130\u2013133. https:\/\/doi.org\/10.1093\/ ced\/llae312","DOI":"10.1093\/ced\/llae312"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tHagino T, Saeki H, Fujimoto E, Kanda N. Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan. J Dermatolog Treat. 2024;35(1):2307489. https:\/\/doi.org\/ 10.1080\/09546634.2024.2307489","DOI":"10.1080\/09546634.2024.2307489"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tDattola A, Sasso FP, Marotta G, et al. Effectiveness and safety of deucravacitinib in moderate-to-severe psoriasis: an Italian multicenter real-life study in the Lazio region. Dermatol Pract Concept. 2026;16(1):7116. https:\/\/doi.org\/ 10.5826\/dpc.1601a7116","DOI":"10.5826\/dpc.1601a7116"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tHagino T, Saeki H, Fujimoto E, Kanda N. Long-term real-world effectiveness of deucravacitinib in psoriasis: a 52-week prospective study stratified by prior apremilast or biologic therapy. J Dermatol. 2025;52(4):634\u2013641. https:\/\/doi.org\/10.1111\/1346-8138.17665","DOI":"10.1111\/1346-8138.17665"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tHagino T, Saeki H, Fujimoto E, Kanda N. One hundred and four-week real-world effectiveness of deucravacitinib 6 mg for genital, scalp, and nail psoriasis: a prospective study in Japan. J Am Acad Dermatol. 2026. https:\/\/doi.org\/ 10.1016\/j.jaad.2026.02.103","DOI":"10.1016\/j.jaad.2026.02.103"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tOkabe Y, Hagino T, Takahashi Y, Saeki H, Fujimoto E, Kanda N. Two-year real-world effectiveness of deucravacitinib 6 mg in psoriasis: a single-center analysis stratified by body mass index or age in a Japanese cohort. J Dermatol. 2026;53(3):496\u2013505. https:\/\/doi.org\/10.1111\/1346-8138.70137","DOI":"10.1111\/1346-8138.70137"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tHagino T, Onda M, Saeki H, Fujimoto E, Kanda N. Real-world 52-week effectiveness of deucravacitinib in psoriasis: a stratified analysis by age and body mass index. J Dermatol. 2025;52(4):663\u2013671. https:\/\/doi.org\/10.1111\/ 1346-8138.17617","DOI":"10.1111\/1346-8138.17617"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tValenzuela Ahumada F, Contreras Aguilera J, Alcayaga de la Ribera F, Cabrera Moraga R, Lecaros Cornejo C. Real-world experience with deucravacitinib in psoriatic patients: the Chilean perspective. An Bras Dermatol. 2026;101(1):501264. https:\/\/doi.org\/10.1016\/j.abd.2025.501264","DOI":"10.1016\/j.abd.2025.501264"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tIbba L, Di Giulio S, Malagoli P, et al. Short-term effectiveness and safety of deucravacitinib in psoriasis: a multicenter real-world study with scalp-specific outcomes-IL PSO (Italian Landscape Psoriasis). Dermatol Ther. 2026;16:2169\u20132180. https:\/\/doi.org\/10.1007\/s13555-026-01711-3","DOI":"10.1007\/s13555-026-01711-3"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.\tArmstrong AW, Lebwohl M, Warren RB, et al. Deucravacitinib in plaque psoriasis: four-year safety and efficacy results from the phase 3 POETYK PSO-1, PSO-2 and long-term extension trials. J Eur Acad Dermatol Venereol. 2025;39(7):1336\u20131351. https:\/\/doi.org\/10.1111\/jdv.20553","DOI":"10.1111\/jdv.20553"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.\tWang J, Derrick KM, Heilman E, Jagdeo J. Successful treatment of severe dystrophic nail psoriasis with deucravacitinib. Cutis. 2024;114(6):196\u2013198. https:\/\/doi.org\/10.12788\/cutis.1142","DOI":"10.12788\/cutis.1142"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tOgdie A, Lonowski S, N\u2019Dri L, Khaychuk V, Schumacher R, Michaud K. Impact of deucravacitinib on scalp psoriasis in a real-world prospective cohort study in the United States. Skin. 2025;9(2):s536. https:\/\/doi.org\/10.25251\/ skin.10.supp.536","DOI":"10.25251\/skin.10.supp.536"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.\tMima Y, Ohtsuka T, Norimatsu Y. Green nail in a patient with psoriasis receiving deucravacitinib. Cureus. 2024;16(12):e75906. https:\/\/doi.org\/10.7759\/cureus.75906","DOI":"10.7759\/cureus.75906"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.\tFeldman SR, Bagel J, Hoffmann M, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: improvement in scalp-related quality of life and symptoms in the phase 3b\/4 multicenter, randomized, double-blinded, placebo-controlled PSORIATYK SCALP trial. Skin. 2024;8(6):s425. https:\/\/doi.org\/10.25251\/skin.8.supp.425","DOI":"10.25251\/skin.8.supp.425"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31.\tBlauvelt A, Rich P, Sofen H, et al. Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: a subset analysis of two phase 3 randomized trials in plaque psoriasis. J Am Acad Dermatol. 2024;90(4):775\u2013782. https:\/\/doi.org\/10.1016\/j.jaad.2023.11.060","DOI":"10.1016\/j.jaad.2023.11.060"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.\tLovell KK, Feldman SR. Response to deucravacitinib in psoriasis patients with prior biologic therapy failures: a retrospective study. J Am Acad Dermatol. 2025;92(2):334\u2013335. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.060","DOI":"10.1016\/j.jaad.2024.09.060"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33.\tTakahashi Y, Hagino T, Saeki H, Fujimoto E, Kanda N. Identifying predictive factors for complete skin clearance at week 52 by deucravacitinib in moderate-to-severe psoriasis: a prospective observational study. Cureus. 2025;17(6):e86044. https:\/\/doi.org\/10.7759\/cureus.86044","DOI":"10.7759\/cureus.86044"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34.\tHagino T, Onda M, Saeki H, Fujimoto E, Kanda N. Predictive factors for responders to deucravacitinib treatment in patients with psoriasis. J Dermatol. 2025;52(3):551\u2013555. https:\/\/doi.org\/10.1111\/1346-8138.17601","DOI":"10.1111\/1346-8138.17601"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35.\tMima Y, Ohtsuka T, Akiyama N, Norimatsu Y. Deucravacitinib improved interstitial pneumonia along with KL-6 reduction in a patient with psoriasis: a case report. Clin Cosmet Investig Dermatol. 2025;18:1677\u20131681. https:\/\/ doi.org\/10.2147\/CCID.S536534","DOI":"10.2147\/CCID.S536534"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36.\tGlatzel C, Strunz PP, Goebeler M, Holl-Wieden A, Schmalzing M, Schmieder A. Case report: effectiveness of deucravacitinib in chronic recurrent multifocal osteomyelitis and concomitant psoriasis. Front Immunol. 2025;16:1480810. https:\/\/doi.org\/10.3389\/fimmu.2025.1480810","DOI":"10.3389\/fimmu.2025.1480810"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37.\tZhang X, Zhang C, Liang J, Liu Y, Xu B, Li C. Deucravacitinib as a monotherapy for concurrent management of psoriasis and chronic spontaneous urticaria. Immunol Res. 2025;73(1):92. https:\/\/doi.org\/10.1007\/s12026-025-09649-y","DOI":"10.1007\/s12026-025-09649-y"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38.\tTan H, Chen X, Ou X, Chen Y. Safety evaluation of deucravacitinib: a real-world analysis based on the FDA adverse event reporting system database. Int J Clin Pharm. 2025;47(6):1821\u20131829. https:\/\/doi.org\/10.1007\/s11096-025-01980-6","DOI":"10.1007\/s11096-025-01980-6"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.\tPunchihewa N, Lee S, Tan CG, Foley P. Pityriasis rosea-like drug eruption secondary to deucravacitinib. JAAD Case Rep. 2024;53:63\u201365. https:\/\/doi.org\/10.1016\/j.jdcr.2024.08.019","DOI":"10.1016\/j.jdcr.2024.08.019"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40.\tZaminski D, Taiwo D, Meehan SA, Weed J. Mycosis fungoides with large cell transformation associated with oral deucravacitinib. JAAD Case Rep. 2024;53:139\u2013141. https:\/\/doi.org\/10.1016\/j.jdcr.2024.09.003","DOI":"10.1016\/j.jdcr.2024.09.003"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"41.\tWatanabe N, Murata T, Sugisawa T, Gomi F, Kanazawa N. Uveitis in a psoriasis vulgaris patient receiving deucravacitinib: a case report. J Cutan Immunol Allergy. 2024;7:12545. https:\/\/doi.org\/10.3389\/jcia.2024.12545","DOI":"10.3389\/jcia.2024.12545"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"42.\tLi M, Wang J, Liu Q, et al. Beyond the dichotomy: understanding the overlap between atopic dermatitis and psoriasis. Front Immunol. 2025;16:1541776. https:\/\/doi.org\/10.3389\/fimmu.2025.1541776","DOI":"10.3389\/fimmu.2025.1541776"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"43.\tMarzouk S, Lio P. Psoriasis and atopic dermatitis overlap: pathogenesis and therapeutic considerations for the clinician. Dermatitis. 2026; https:\/\/doi.org\/10.1177\/17103568251378145","DOI":"10.1177\/17103568251378145"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"44.\tTang JT, Xu MY, Wu NH, Wu F, Liu YQ. Rapid clinical improvement with tyrosine kinase 2 inhibitor deucravacitinib in overlapping psoriasis and atopic dermatitis. Int J Dermatol. 2025;64(7):1270\u20131273. https:\/\/doi.org\/10.1111\/ijd.17742","DOI":"10.1111\/ijd.17742"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"45.\tZhang Y, Jiang G. Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses. Front Immunol. 2024;15:1341632. https:\/\/doi.org\/10.3389\/fimmu.2024.1341632","DOI":"10.3389\/fimmu.2024.1341632"},{"key":"ref45","unstructured":"46.\tNational Library of Medicine. A real-world study of deucravacitinib in the treatment of moderate to severe plaque psoriasis with eczematous features. https:\/\/clinicaltrials.gov\/study\/NCT06999941. Accessed March 21, 2026."},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47.\tM\u00fcller S, Welchowski T, Schmid M, et al. Development of a clinical algorithm to predict phenotypic switches between atopic dermatitis and psoriasis (the \u201cFlip-Flop\u201d phenomenon). Allergy. 2024;79(1):164\u2013173. https:\/\/ doi.org\/10.1111\/all.15921","DOI":"10.1111\/all.15921"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48.\tLugli AP, Gori N, Ippoliti E, Ambrosio B, Peris K. Upadacitinib as a potential option for the management of paradoxical eczema induced by interleukin-23 inhibitors. Dermatol Rep. 2026. https:\/\/doi.org\/10.4081\/ dr.2026.10644","DOI":"10.4081\/dr.2026.10644"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"49.\tGisondi P, Bellinato F. Management of IL-17 inhibitors-induced paradoxical eczema in patients with plaque psoriasis. J Eur Acad Dermatol Venereol. 2025;40(5):e401\u2013e404. https:\/\/doi.org\/10.1111\/jdv.70198","DOI":"10.1111\/jdv.70198"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"50.\tTous-Romero F, Calvo-As\u00edn C. Overlap between psoriasis and atopic dermatitis: therapeutic approach. Actas Dermosifiliogr. 2026;117(3):104541. https:\/\/doi.org\/10.1016\/j.ad.2025.104541","DOI":"10.1016\/j.ad.2025.104541"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"51.\tTsunoda M, Adachi T, Nakajima Y, Yatomi Y, Shimizu T, Nakasute K. Successful treatment of the dupilumab-induced psoriatic dermatitis\/arthritis and atopic dermatitis with a JAK inhibitor: a case report and literature review. J Allergy Clin Immunol Glob. 2024;3(4):100323. https:\/\/doi.org\/10.1016\/j.jacig.2024.100323","DOI":"10.1016\/j.jacig.2024.100323"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"52.\tGuel T, de Vos-Hillebrand L, Wilsmann-Theis D, Novak N, Wenzel J. Successful treatment of erythroderma in a psoriasis patient, developed after anti-IL-17, anti-IL-23 and anti-IL-4\/IL-13 treatment, with deucravacitinib. JEADV Clin Pract. 2025;4:858\u2013861. https:\/\/doi.org\/10.1002\/jvc2.70037","DOI":"10.1002\/jvc2.70037"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"53.\tKavanaugh A, Coates LC, Mease PJ, et al. Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial. Rheumatology. 2025;64(5):2557\u20132564. https:\/\/doi.org\/10.1093\/rheumatology\/keae580","DOI":"10.1093\/rheumatology\/keae580"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"54.\tMease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81:815\u201322. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221664","DOI":"10.1136\/annrheumdis-2021-221664"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"55.\tDimopoulou V, Nitsa M, Koutsianas C. Emerging targets in psoriatic arthritis: dual IL-17A\/F and selective TYK2 inhibition in a clinical perspective. Mediterr J Rheumatol. 2026;37(Suppl. 1):68\u201376. https:\/\/doi.org\/10.31138\/mjr.101025.erh","DOI":"10.31138\/mjr.101025.erh"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"56.\tVan der Heijde D, Mease PJ, Paul C, et al. LB0001 Efficacy and safety of deucravacitinib up to week 16 from Poetyk PSA-1: a multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with active psoriatic arthritis. Ann Rheum Dis. 2025;84(Suppl. 1):313\u2013314. https:\/\/doi.org\/10.1016\/j.ard.2025.05.388","DOI":"10.1016\/j.ard.2025.05.388"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"57.\tMease P, Chandran V, Armstrong A, et al. OP0095 Efficacy and safety of deucravacitinib up to week 52 from POETYK PsA-2: a multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with psoriatic arthritis. Ann Rheum Dis. 2025;84(Suppl. 1):84\u201385. https:\/\/doi.org\/10.1016\/j.ard.2025.05.117","DOI":"10.1016\/j.ard.2025.05.117"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"58.\tMerola JF, Mease PJ, Armstrong AW, et al. Deucravacitinib in patients with plaque psoriasis who screened positive for psoriatic arthritis: improvements in joint pain and the impact of musculoskeletal symptoms. Dermatol Ther. 2025;15(8):2281\u20132293. https:\/\/doi.org\/10.1007\/s13555-025-01428-9","DOI":"10.1007\/s13555-025-01428-9"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"59.\tKodaka E, Sekine S, Higashida S, et al. Successful management of multidrug-resistant psoriatic arthritis coexisting with rheumatoid arthritis using a TYK2 inhibitor deucravacitinib-based regimen. J Dermatol. 2025;52(8):e732\u2013e734. https:\/\/doi.org\/10.1111\/1346-8138.17808","DOI":"10.1111\/1346-8138.17808"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"60.\tGewiss C, Steinmetz OM, Roth L, Augustin M, Ben-Anaya N. Effective management of psoriasis and psoriatic arthritis in a patient with systemic lupus erythematosus using deucravacitinib, mycophenolate mofetil and hydroxychloroquine. Skin Health Dis. 2025;5(5):403\u2013405. https:\/\/doi.org\/10.1093\/skinhd\/vzaf058","DOI":"10.1093\/skinhd\/vzaf058"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"61.\tMartins A, L\u00e9 AM, Torres T. Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far. Drugs Context. 2023;12:2023-2-7. https:\/\/doi.org\/10.7573\/dic.2023-2-7","DOI":"10.7573\/dic.2023-2-7"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"62.\tWasserer S, Seiringer P, Kurzen N, et al. Tyrosine kinase 2 inhibition improves clinical and molecular hallmarks in subtypes of cutaneous lupus. Br J Dermatol. 2025;193(6):1192\u20131203. https:\/\/doi.org\/10.1093\/bjd\/ljaf293","DOI":"10.1093\/bjd\/ljaf293"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"63.\tBokor LA, Martyin K, Krebs M, et al. Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules \u2014 a systematic review and meta-analysis. Autoimmun Rev. 2025;24(3):103723. https:\/\/doi.org\/10.1016\/j.autrev.2024.103723","DOI":"10.1016\/j.autrev.2024.103723"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"64.\tBuffon S, Genovese G, Derlino F, et al. Deucravacitinib for the treatment of cutaneous lupus erythematosus: a 9-patient case series. Clin Exp Dermatol. 2026. https:\/\/doi.org\/10.1093\/ced\/llag095","DOI":"10.1093\/ced\/llag095"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"65.\tBouch\u00e9 N, Al-Saedy MA, Song EJ. Successful treatment of refractory subacute cutaneous lupus erythematosus with deucravacitinib. JAAD Case Rep. 2023;39:93\u201395. https:\/\/doi.org\/10.1016\/j.jdcr.2023.07.030","DOI":"10.1016\/j.jdcr.2023.07.030"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"66.\tKurz B, Ivanova I, Drexler K, Berneburg M, G\u00fcnther F, Niebel D. Rapid clinical improvement of refractory subacute cutaneous lupus erythematosus with oral tyrosine kinase 2 inhibitor deucravacitinib: a case report. J Eur Acad Dermatol Venereol. 2024;38(5):e434\u2013e436. https:\/\/doi.org\/10.1111\/jdv.19667","DOI":"10.1111\/jdv.19667"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"67.\tZhang A, Gaffney RG, Merola JF. Treatment of recalcitrant lupus erythematosus tumidus with deucravacitinib. JAAD Case Rep. 2023;45:110\u2013112. https:\/\/doi.org\/10.1016\/j.jdcr.2023.11.029","DOI":"10.1016\/j.jdcr.2023.11.029"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"68.\tEzeh N, Vleugels RA, Shahriari N. Discoid lupus erythematosus successfully treated with deucravacitinib. JAAD Case Rep. 2024;49:59\u201361. https:\/\/doi.org\/10.1016\/j.jdcr.2024.04.032","DOI":"10.1016\/j.jdcr.2024.04.032"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"69.\tAw K, Gavigan G. Treatment of discoid lupus erythematosus scarring alopecia with deucravacitinib: a case report. SAGE Open Med Case Rep. 2025;13:2050313X241304891. https:\/\/doi.org\/10.1177\/2050313X241304891","DOI":"10.1177\/2050313X241304891"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"70.\tAssaf K, Patt S, Sch\u00e4fer VS, Wenzel J, Novak N, Wilsmann-Theis D. Successful treatment of subacute cutaneous lupus erythematosus with the TYK-2 inhibitor deucravacitinib in a patient with concomitant psoriasis vulgaris. J Dtsch Dermatol Ges. 2025;23(7):874\u2013877. https:\/\/doi.org\/10.1111\/ddg.15705","DOI":"10.1111\/ddg.15705"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"71.\tHren GM, Silva I, Adalsteinsson JA, Khattri S. Use of Deucravacitinib in cutaneous lupus erythematosus: two patient experiences at a combined rheumatology-dermatology clinic. Int J Dermatol. 2025;64(11):2104\u20132106. https:\/\/ doi.org\/10.1111\/ijd.17817","DOI":"10.1111\/ijd.17817"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"72.\tMatthew EJ, Verma KK, Paulger B. Oral deucravacitinib for treatment-refractory cutaneous lupus erythematosus. Cureus. 2025;17(3):e81539. https:\/\/doi.org\/10.7759\/cureus.81539","DOI":"10.7759\/cureus.81539"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"73.\tTjiu JW, Tsai TF. Systemic treatment strategies for patients with psoriasis and psoriatic arthritis in the setting of ANA positivity or lupus spectrum disease: a comprehensive systematic review. Int J Mol Sci. 2026;27(2):1093. https:\/\/ doi.org\/10.3390\/ijms27021093","DOI":"10.3390\/ijms27021093"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"74.\tMosca M, Arnaud L, Askanase A, et al. Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial. Lupus Sci Med. 2025;12(1):e001517. https:\/\/doi.org\/10.1136\/lupus-2025-001517","DOI":"10.1136\/lupus-2025-001517"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"75.\tArriens C, Morand EF, Askanase AD, et al. Design of two randomized, placebo-controlled, phase 3 trials of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in systemic lupus erythematosus. Adv Ther. 2025;42(11):5830\u20135844. https:\/\/doi.org\/10.1007\/s12325-025-03299-0","DOI":"10.1007\/s12325-025-03299-0"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"76.\tMima Y, Yamamoto M, Iozumi K. Review of promising off-label use of deucravacitinib. Int J Mol Sci. 2025;26(19):9447. https:\/\/doi.org\/10.3390\/ijms26199447","DOI":"10.3390\/ijms26199447"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"77.\tL\u00f3pez-Isac E, Campillo-Davo D, Bossini-Castillo L, et al. Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway. Ann Rheum Dis. 2016;75(8):1521\u20131526. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208154","DOI":"10.1136\/annrheumdis-2015-208154"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"78.\tFukasawa T, Yoshizaki-Ogawa A, Yoshizaki A, Sato S. The effects of deucravacitinib on three cases of systemic sclerosis associated with psoriasis. Rheumatology. 2025;64(6):4067\u20134069. https:\/\/doi.org\/10.1093\/rheumatology\/keaf019","DOI":"10.1093\/rheumatology\/keaf019"},{"key":"ref78","unstructured":"79.\tQudsiya Z, Waseem M. Dermatomyositis. In: StatPearls. Treasure Island, FL: StatPearls; 2023. https:\/\/ pubmed.ncbi.nlm.nih.gov\/32644343\/. Accessed May 28, 2026."},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"80.\tBurli A, Marin BG, Newman E, Tahir Z, Fiorentino DF. Novel use of deucravacitinib for treatment of recalcitrant TIF1- gamma dermatomyositis. JAAD Case Rep. 2025;66:190\u2013192. https:\/\/doi.org\/10.1016\/j.jdcr.2025.10.010","DOI":"10.1016\/j.jdcr.2025.10.010"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"81.\tMcNamara ME, Tjahjono L. Successful treatment of recalcitrant amyopathic dermatomyositis with deucravacitinib in addition to intravenous immunoglobulin. JAAD Case Rep. 2025;62:6\u20138. https:\/\/doi.org\/10.1016\/j.jdcr.2025.01.047","DOI":"10.1016\/j.jdcr.2025.01.047"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"82.\tLapa T, Breslavets M. Successful treatment of refractory dermatomyositis with deucravacitinib (Sotyktu): a case report. Case Rep Dermatol. 2025;17(1):444\u2013449. https:\/\/doi.org\/10.1159\/000548207","DOI":"10.1159\/000548207"},{"key":"ref82","unstructured":"83.\tNational Library of Medicine. Study of deucravacitinib for refractory adults with dermatomyositis\/juvenile dermatomyositis. https:\/\/clinicaltrials.gov\/study\/NCT07012057?tab=study. Accessed March 2, 2026."},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"84.\tRudnicka L, Arenbergerova M, Grimalt R, et al. European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2024;38(4):687\u2013694. https:\/\/doi.org\/10.1111\/jdv.19768","DOI":"10.1111\/jdv.19768"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"85.\tSanchez K, Englander H, Salloum L, et al. Evaluating current and emergent JAK inhibitors for alopecia areata: a narrative review. Dermatol Ther. 2025;15(10):2749\u20132764. https:\/\/doi.org\/10.1007\/s13555-025-01517-9","DOI":"10.1007\/s13555-025-01517-9"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"86.\tOliel S, Moussa S, Stanciu M, Netchiporouk E. Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: a case report. SAGE Open Med Case Rep. 2023;11:2050313X231213135. https:\/\/doi.org\/10.1177\/ 2050313X231213135","DOI":"10.1177\/2050313X231213135"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"87.\tJonas C, Sch\u00f6n MP, M\u00f6ssner R. Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy. J Dtsch Dermatol Ges. 2025;23(2):234\u2013235. https:\/\/doi.org\/10.1111\/ddg.15603","DOI":"10.1111\/ddg.15603"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"88.\tYong SS, Bhoyrul B. Complete hair regrowth in a patient with severe alopecia areata treated with deucravacitinib. Clin Exp Dermatol. 2025;50(12):2501\u20132502. https:\/\/doi.org\/10.1093\/ced\/llaf345","DOI":"10.1093\/ced\/llaf345"},{"key":"ref88","unstructured":"89.\tNational Library of Medicine. A study to evaluate efficacy and safety of deucravacitinib in participants with alopecia areata. https:\/\/clinicaltrials.gov\/study\/NCT05556265?tab=study. Accessed March 2, 2026."},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"90.\tPotestio L, D\u2019Agostino M, Portarapillo A, et al. Emerging role of biologic drugs targeting IL-17 and IL-23: pityriasis rubra pilaris. Life. 2024;14(8):923. https:\/\/doi.org\/10.3390\/life14080923","DOI":"10.3390\/life14080923"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"91.\tChen LY, Mai SZ, Wu XY, et al. Cytokine-associated pathogenic profile as a guide for targeted therapy in pityriasis rubra pilaris. J Eur Acad Dermatol Venereol. 2025;40(6):e473\u2013e475. https:\/\/doi.org\/10.1111\/jdv.70221","DOI":"10.1111\/jdv.70221"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"92.\tZhang X, Wei K, Song H, et al. Efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris \u2014 a systematic review. Front Med. 2025;12:1544197. https:\/\/doi.org\/10.3389\/fmed.2025.1544197","DOI":"10.3389\/fmed.2025.1544197"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"93.\tTaremi M, Mozafari N. Tofacitinib: a promising therapeutic option for refractory pityriasis rubra pilaris \u2014 a case report. Clin Case Rep. 2025;13(10):e71232. https:\/\/doi.org\/10.1002\/ccr3.71232","DOI":"10.1002\/ccr3.71232"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"94.\tTan H, Zhang B, Kang X, Wang L, Qiu X, Hu X. Tofacitinib for pityriasis rubra pilaris: a case report. Clin Cosmet Investig Dermatol. 2024;17:1917\u20131920. https:\/\/doi.org\/10.2147\/CCID.S470170","DOI":"10.2147\/CCID.S470170"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"95.\tYing Y, Yu-Hua L, Xiao-Yan W, Su-Chun H. A case of pityriasis rubra pilaris treated with tofacitinib after failure with acitretin and ixekizumab. Australas J Dermatol. 2023;64(3):445\u2013447. https:\/\/doi.org\/10.1111\/ajd.14076","DOI":"10.1111\/ajd.14076"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"96.\tLi Y, Chen Z, He M, et al. Successful treatment of erythrodermic pityriasis rubra pilaris with upadacitinib. J Eur Acad Dermatol Venereol. 2024;38(7):e593\u2013e595. https:\/\/doi.org\/10.1111\/jdv.19762","DOI":"10.1111\/jdv.19762"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"97.\tLi Y, Guo M, Sheng Z, et al. Case report: successful treatment of pityriasis rubra pilaris with deucravacitinib. Front Immunol. 2026;17:1752884. https:\/\/doi.org\/10.3389\/fimmu.2026.1752884","DOI":"10.3389\/fimmu.2026.1752884"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"98.\tJin S, Jin S, Wang P. Successful treatment of pityriasis rubra pilaris with deucravacitinib. JAMA Dermatol. 2026;162(3):318\u2013319. https:\/\/doi.org\/10.1001\/jamadermatol.2025.5224","DOI":"10.1001\/jamadermatol.2025.5224"},{"key":"ref98","unstructured":"99.\tNational Library of Medicine. Deucravacitinib (BMS-986165) for pityriasis rubra pilaris. https:\/\/clinicaltrials.gov\/ study\/NCT06444399?tab=study. Accessed March 6, 2026."},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"100.\tLee MJ, Avenido MIP, Ames E, Cotter DG. Rapid and successful treatment of generalized granuloma annulare with deucravacitinib. Cureus. 2025;17(12):e98761. https:\/\/doi.org\/10.7759\/cureus.98761","DOI":"10.7759\/cureus.98761"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"101.\tLapa T, Breslavets M. Generalized granuloma annulare successfully treated with deucravacitinib (Sotyktu). JAAD Case Rep. 2025;60:79\u201382. https:\/\/doi.org\/10.1016\/j.jdcr.2025.02.034","DOI":"10.1016\/j.jdcr.2025.02.034"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"102.\tWang A, Rahman NT, McGeary MK, et al. Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib. J Allergy Clin Immunol. 2021;147(5):1795\u20131809. https:\/\/doi.org\/10.1016\/j.jaci.2020.10.012","DOI":"10.1016\/j.jaci.2020.10.012"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"103.\tLiu W, Chen W, Tian X, et al. Oral abrocitinib in the treatment of granuloma annulare: a case report. J Dermatolog Treat. 2024;35(1):2313090. https:\/\/doi.org\/10.1080\/09546634.2024.2313090","DOI":"10.1080\/09546634.2024.2313090"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"104.\tGiorgio CM, Balato A, Licata G, Tancredi V, Argenziano G, Di Brizzi EV. Successful treatment of refractory generalized granuloma annulare with abrocitinib. Dermatol Rep. 2026. https:\/\/doi.org\/10.4081\/dr.2026.10296","DOI":"10.4081\/dr.2026.10296"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"105.\tGreene L, Lane JE. Cutaneous sarcoidosis. Am J Med. 2026;139(7):e187\u2013e188. https:\/\/doi.org\/10.1016\/ j.amjmed.2026.01.028","DOI":"10.1016\/j.amjmed.2026.01.028"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"106.\tHerrera HO, Sanchez C, Minor G, Fulchiero GJ Jr. Successful treatment of cutaneous sarcoidosis with deucravacitinib, a selective TYK2 inhibitor. JAAD Case Rep. 2025;67:165\u2013167. https:\/\/doi.org\/10.1016\/j.jdcr.2025.10.058","DOI":"10.1016\/j.jdcr.2025.10.058"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"107.\tDamsky W, Young BD, Sloan B, Miller EJ, Obando JA, King B. Treatment of multiorgan sarcoidosis with tofacitinib. ACR Open Rheumatol. 2020;2(2):106\u2013109. https:\/\/doi.org\/10.1002\/acr2.11112","DOI":"10.1002\/acr2.11112"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"108.\tRotenberg C, Besnard V, Brillet PY, Giraudier S, Nunes H, Valeyre D. Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia. Eur Respir J. 2018;52(6):1801482. https:\/\/ doi.org\/10.1183\/13993003.01482-2018","DOI":"10.1183\/13993003.01482-2018"},{"key":"ref108","unstructured":"109.\tNational Library of Medicine. Tyrosine Kinase 2 (TYK2) for GA and CS. https:\/\/clinicaltrials.gov\/study\/NCT06725264. Accessed March 8, 2026."},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"110.\tAlarc\u00f3n I, Alarc\u00f3n C, Arellano J. Overview of lichen planus pathogenesis and review of possible future therapies. JAAD Rev. 2025;3:P146\u2013P154. https:\/\/doi.org\/10.1016\/j.jdrv.2025.01.011","DOI":"10.1016\/j.jdrv.2025.01.011"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"111.\tSood S, Yadav G. Treatment of hypertrophic lichen planus using deucravacitinib. JAAD Case Rep. 2024;51:38\u201340. https:\/\/doi.org\/10.1016\/j.jdcr.2024.06.013","DOI":"10.1016\/j.jdcr.2024.06.013"},{"key":"ref111","doi-asserted-by":"crossref","unstructured":"112.\tBall GD, Golant A. A case of extensive lichen planus treated with deucravacitinib. Cureus. 2024;16(10):e71951. https:\/\/ doi.org\/10.7759\/cureus.71951","DOI":"10.7759\/cureus.71951"},{"key":"ref112","unstructured":"113.\tMachynia K, Mpas P, Hawkes JE. Clearance of cutaneous lichen planus with deucravacitinib. J Clin Aesthet Dermatol. 2026;19(2):47\u201349."},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"114.\tGaumond S, Romanelli P. 62956 Successful treatment of recalcitrant cutaneous and mucosal lichen planus with deucravacitinib: a case report. J Am Acad Dermatol. 2025;93(3):AB84. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.339","DOI":"10.1016\/j.jaad.2025.05.339"},{"key":"ref114","doi-asserted-by":"crossref","unstructured":"115.\tVu M, Abdin R, Issa NT. Treatment of oral lichen planus using deucravacitinib. JAAD Case Rep. 2023;44:94\u201397. https:\/\/doi.org\/10.1016\/j.jdcr.2023.12.006","DOI":"10.1016\/j.jdcr.2023.12.006"},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"116.\tStolte KN, Mesas-Fern\u00e1ndez A, Meier K, et al. TYK2 inhibition with deucravacitinib ameliorates erosive oral lichen planus. Exp Dermatol. 2024;33(4):e15080. https:\/\/doi.org\/10.1111\/exd.15080","DOI":"10.1111\/exd.15080"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"117.\tJu D, Zhou L, Liu X, et al. Treatment of lichen planopilaris with the TYK-2 inhibitor deucravacitinib. J Am Acad Dermatol. 2026;94(2):678\u2013680. https:\/\/doi.org\/10.1016\/j.jaad.2025.10.047","DOI":"10.1016\/j.jaad.2025.10.047"},{"key":"ref117","doi-asserted-by":"crossref","unstructured":"118.\tAbduelmula A, Bagit A, Mufti A, Yeung KCY, Yeung J. The use of janus kinase inhibitors for lichen planus: an evidence-based review. J Cutan Med Surg. 2023;27(3):271\u2013276. https:\/\/doi.org\/10.1177\/12034754231156100","DOI":"10.1177\/12034754231156100"},{"key":"ref118","unstructured":"119.\tNational Library of Medicine. A study of deucravacitinib to treat LPP and FFA. https:\/\/clinicaltrials.gov\/study\/ NCT06091956?tab=study. Accessed March 8, 2026."},{"key":"ref119","doi-asserted-by":"crossref","unstructured":"120.\tWang H, Zhou C. Advances in the pathogenesis of rosacea. Front Immunol. 2026;16:1705588. https:\/\/doi.org\/ 10.3389\/fimmu.2025.1705588","DOI":"10.3389\/fimmu.2025.1705588"},{"key":"ref120","doi-asserted-by":"crossref","unstructured":"121.\tWarren Z, West C, Sander C, Lai FYX. TYK-ed off by rosacea: an Australian case series of rosacea associated with deucravacitinib. Clin Exp Dermatol. 2025;50(12):2482\u20132485. https:\/\/doi.org\/10.1093\/ced\/llaf418","DOI":"10.1093\/ced\/llaf418"},{"key":"ref121","doi-asserted-by":"crossref","unstructured":"122.\tThomas M, Paranjape M, Sinclair R. Rosacea fulminans following initiation of deucravacitinib. Clin Exp Dermatol. 2025;50(5):1031\u20131032. https:\/\/doi.org\/10.1093\/ced\/llae495","DOI":"10.1093\/ced\/llae495"},{"key":"ref122","doi-asserted-by":"crossref","unstructured":"123.\tXu Y, Liu X, Guo L, Jiang X. Adverse events associated with apremilast and deucravacitinib for psoriasis: a pharmacovigilance study based on the FAERS database. Clin Cosmet Investig Dermatol. 2025;18:1121\u20131135. https:\/\/ doi.org\/10.2147\/CCID.S439643","DOI":"10.2147\/CCID.S439643"},{"key":"ref123","doi-asserted-by":"crossref","unstructured":"124.\tMartinez J, Manjaly C, Manjaly P, et al. Janus kinase inhibitors and adverse events of acne: a systematic review and meta-analysis. JAMA Dermatol. 2023;159(12):1339\u20131345. https:\/\/doi.org\/10.1001\/jamadermatol.2023.3830","DOI":"10.1001\/jamadermatol.2023.3830"},{"key":"ref124","doi-asserted-by":"crossref","unstructured":"125.\tTran V, Wong C, Lee S, Rodrigues M. Acneiform eruption secondary to deucravacitinib: a case series and review of the literature. Australas J Dermatol. 2025;66(3):157\u2013161. https:\/\/doi.org\/10.1111\/ajd.14425","DOI":"10.1111\/ajd.14425"},{"key":"ref125","doi-asserted-by":"crossref","unstructured":"126.\tMisiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments. Am J Clin Dermatol. 2020;21(3):355\u2013370. https:\/\/doi.org\/10.1007\/s40257-020-00503-5","DOI":"10.1007\/s40257-020-00503-5"},{"key":"ref126","doi-asserted-by":"crossref","unstructured":"127.\tBrunasso AMG, Massone C. Recent advances in palmoplantar pustulosis. Fac Rev. 2021;10:62. https:\/\/doi.org\/ 10.12703\/r\/10-62","DOI":"10.12703\/r\/10-62"},{"key":"ref127","doi-asserted-by":"crossref","unstructured":"128.\tVimbai Chirindo C, Yun-Jie W, Tauseef H, Chao C, Tao Y. Targeting the JAK\/STAT pathway in palmoplantar pustulosis: a review. Ann Med. 2025;57(1):2594352. https:\/\/doi.org\/10.1080\/07853890.2025.2594352","DOI":"10.1080\/07853890.2025.2594352"},{"key":"ref128","doi-asserted-by":"crossref","unstructured":"129.\tDe Luca DA, Papara C, Hawro T, Tha\u00e7i D, St\u00e4nder S. Exploring the effect of deucravacitinib in patients with palmoplantar pustular psoriasis. J Dermatolog Treat. 2024;35(1):2399220. https:\/\/doi.org\/10.1080\/09546634.2024.2399220","DOI":"10.1080\/09546634.2024.2399220"},{"key":"ref129","doi-asserted-by":"crossref","unstructured":"130.\tRamessur R, Chiesa Fuxench ZC, Shin D, et al. Deucravacitinib for the treatment of moderate-to-severe palmoplantar pustulosis: results from an early-terminated open-label trial. JAAD Int. 2025;24:84\u201386. https:\/\/ doi.org\/10.1016\/j.jdin.2025.09.015","DOI":"10.1016\/j.jdin.2025.09.015"},{"key":"ref130","doi-asserted-by":"crossref","unstructured":"131.\tPan Y, Jin D, Meng F, et al. From apremilast to JAK inhibitors-salvage treatment strategies for refractory palmoplantar pustulosis: case series. Front Med. 2026;13:1743408. https:\/\/doi.org\/10.3389\/fmed.2026.1743408","DOI":"10.3389\/fmed.2026.1743408"},{"key":"ref131","unstructured":"132.\tKalola UK, Alberty A, Sheehy C. Deucravacitinib. In: StatPearls. Treasure Island, FL: StatPearls; 2024. https:\/\/ www.ncbi.nlm.nih.gov\/books\/NBK606109\/. Accessed May 5, 2026."},{"key":"ref132","doi-asserted-by":"crossref","unstructured":"133.\tBabaei N, Kim D, Cervantes M, Yang S, Gill M, Wu JJ. A review of phase III and long-term data for deucravacitinib for plaque psoriasis. Int J Dermatol. 2026;65(2):238\u2013244. https:\/\/doi.org\/10.1111\/ijd.70023","DOI":"10.1111\/ijd.70023"},{"key":"ref133","doi-asserted-by":"crossref","unstructured":"134.\tDeleuran M, Vestergaard C. Real-world evidence vs. randomized control trials. Br J Dermatol. 2020;182(2):275\u2013276. https:\/\/doi.org\/10.1111\/bjd.18791","DOI":"10.1111\/bjd.18791"},{"key":"ref134","unstructured":"135.\tKatz A, Kircik C, Lamb A, Armstrong A. INDIVIDUAL ARTICLE: evidence-based synthesis of deucravacitinib: long term efficacy, safety, and practical use in moderate-to-severe psoriasis. J Drugs Dermatol. 2026;25(2):70210s3-70210s10."},{"key":"ref135","doi-asserted-by":"crossref","unstructured":"136.\tAndrzejczak K, Sternak A, Witkowski W, Karolewicz B, Ponikowska M. From convenience to clinical efficacy: selective tyk2 inhibition in psoriasis and the evolving role of next-generation oral targeted therapies. Pharmaceutics. 2026;18(3):347. https:\/\/doi.org\/10.3390\/pharmaceutics18030347","DOI":"10.3390\/pharmaceutics18030347"},{"key":"ref136","doi-asserted-by":"crossref","unstructured":"137.\tBang CH, Park CJ, Kim YS. The expanding therapeutic potential of deucravacitinib beyond psoriasis: a narrative review. J Clin Med. 2025;14(5):1745. https:\/\/doi.org\/10.3390\/jcm14051745","DOI":"10.3390\/jcm14051745"},{"key":"ref137","unstructured":"138.\tNational Library of Medicine. A study to evaluate the efficacy a nd safety of deucravacitinib in adults with active Sj\u00f6gren\u2019s syndrome (POETYK SjS-1). https:\/\/clinicaltrials.gov\/study\/NCT05946941. Accessed March 30, 2026."},{"key":"ref138","unstructured":"139.\tNational Library of Medicine. A study to evaluate efficacy and safety of deucravacitinib in participants with active discoid and\/or subacute cutaneous lupus erythematosus (DLE\/SCLE). https:\/\/clinicaltrials.gov\/study\/ NCT04857034. Accessed March 30, 2026."},{"key":"ref139","doi-asserted-by":"crossref","unstructured":"140.\tD\u2019Haens G, Danese S, Panaccione R, et al. Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn\u2019s disease and ulcerative colitis. J Crohns Colitis. 2025;19(6):jjaf080. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf080","DOI":"10.1093\/ecco-jcc\/jjaf080"},{"key":"ref140","unstructured":"141.\tEuropean Clinical Trials Information Network. Study on the effects of deucravacitinib for adults with inflammatory skin conditions (epidermolysis bullosa simplex and congenital ichthyoses). https:\/\/clinicaltrials.eu\/trial\/study-on-the-effects-of-deucravacitinib-for-adults-with-inflammatory-skin-conditions-epidermolysis-bullosa-simplex-and-congenital-ichthyoses\/. Accessed March 30, 2026."}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/06\/dic.2026-4-1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:56:14Z","timestamp":1788947774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/deucravacitinib-in-dermatology-current-indication-and-existing-off-label-data"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":141,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-4-1","relation":{},"ISSN":["1740-4398","1740-4398"],"issn-type":[{"value":"1740-4398","type":"print"},{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"dic.2026-4-1"}}